Recent studies have highlighted the potential of ROCK2 inhibition as a promising therapeutic approach for immune-associated diseases such as systemic lupus erythematosus (SLE), IBD, and chronic GVHD [45,46,47]. The gene discussed is ROCK2; the disease is chronic graft versus host disease.